Search - sphingotec.com

81. Bioactive Adrenomedullin, measured with sphingotec’s bio-ADM® assay plays a key role in septic shock patients as top-line results of AdrenOSS-2 Phase II Study indicate

Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf, Germany) today announced that data from the AdrenOSS-2 study indicate a modulating role of bioactive Adrenomedullin in septic…

82. Novel Data on SphingoTec's Biomarkers for acute and critical care setting to be presented at AKI & CRRT 2020

SphingoTec GmbH (“sphingotec”) today announced that novel data on its acute care biomarkers Proenkephalin (penKid®) and Dipeptidyl Peptidase 3 (DPP3) will be presented at the 25th International…

83. SphingoTec's biomarker penKid® shows best representation of true glomerular filtration rate and has utility in patients with sever burns two studies show

Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf Germany) today announced the publication of two studies demonstrating that its kidney function biomarker Proenkephalin (penKid®) is the…

84. Hitado GmbH becomes Nexus IB10 distributor for Sphingotec in Germany an Switzerland

Hitado GmbH (Hitado), a Sysmex point-of-care subsidiary, and SphingoTec GmbH (sphingotec) have signed an exclusive distribution agreement for the commercialisation of the Nexus IB10 diagnostic…

85. SphingoTec launches IVD Test for Kidney Function Biomarker penKid® on Nexus IB10 POCT Platform

Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf near Berlin, Germany) today announced the launch of its IB10 sphingotest® penKid®, a CE-IVD-marked point-of-care test for Proenkephalin…

86. SphingoTec transforms into end-to-end diagnostic solutions provider and exclusively represents Nexus Dx IB10 immunoassay portfolio

The German diagnostics company sphingotec GmbH (Hennigsdorf, Germany) today announced that through its network of regional and local distribution partners it will exclusively offer the Nexus Dx IB10…

87. sphingotec’s endothelial function biomarker bio-ADM® predicts need for organ support in general ICU patient population

Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf, Germany) today announced a publication in Critical Care1 with data on 2,000 ICU patients demonstrating that sphingotec‘s…

88. sphingotec’s biomarker penKid® predicts septic acute kidney injury at time of admission to emergency department

Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf Germany) today reported on the publication of novel study results of its proprietary kidney function biomarker penKid® in BMC…

89. sphingotec’s proprietary biomarker bio-ADM® detects residual congestion in patients with heart failure

Diagnostics company SphingoTec GmbH (sphingotec) today announced the publication of new study results in the European Journal of Heart Failure demonstrating that its proprietary endothelial function…

90. SphingoTec to Present Novel Acute Care Biomarkers and Point-of-Care Diagnostic Solutions at Medica 2019

SphingoTec GmbH (“sphingotec”) today announced that latest advancements in the development of its portfolio of novel biomarkers and diagnostic solutions will be showcased at Medica 2019 in…